DCVC BIO
DCVC BIO is a Pre-seed, Seed and Series A fund in the US writing $5M–$25M checks into AI, Healthcare, synthetic-biology, agriculture, biotechnology, drug-discovery, genetics, chemistry, molecular-biology and industrial-fermentation.
- Stages
- Pre-seed, Seed, Series A
- Sectors
- AI, Healthcare, synthetic-biology, agriculture, biotechnology, drug-discovery, genetics, chemistry, molecular-biology, industrial-fermentation
- Check size
- $5M–$25M
- Invests in
- US-wide
- Actively investing
- Yes
- Founded
- 2018
- Assets under management
- $500M
- Website
- dcvc.com
Thesis
DCVC Bio, a division of DCVC, is a venture capital firm founded in 2018, specializing in early-stage deep technology life sciences startups. They focus on scientist-led companies using computational approaches, AI, and advanced scientific principles to solve real-world problems in human health, agriculture, and synthetic biology. Primarily based in North America with headquarters in San Francisco, CA, they invest in pre-seed, seed, and Series A rounds, often leading investments. Their strategy involves a deep understanding of genetics, chemistry, molecular biology, agriculture, industrial fermentation, and AI. DCVC Bio manages approximately $500 million in AUM and typically invests $5 million to $25 million per company. They aim to unify data and transform life sciences technologies to create a more just, flourishing, and sustainable world.
Common questions
Does DCVC BIO invest at the Pre-seed stage?
Yes. DCVC BIO lists Pre-seed, Seed and Series A among the stages it invests in.
What check size does DCVC BIO write?
DCVC BIO writes $5M–$25M checks.
Where does DCVC BIO invest?
DCVC BIO invests in the US.